BioSpace News Archive

L’Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM), the national authority for authorizing medicinal products in France, has granted “accès compassionnel” (compassionate access) to AMX0035 (sodium phenylbutyrate and ursodoxicoltaurine [also known as taurursodiol]) for eligible people living with amyotrophic lateral sclerosis (ALS) following a collaborative process involving medical experts, ARSLA and other ALS advocates, ANSM, and Amylyx.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit in New York City on Wednesday, October 11, 2023.

KDx Diagnostics Inc., a leading innovator in non-invasive bladder cancer tests, is pleased to announce the issuance of important patents in the US, EU, and South Korea relating to their joint work in developing new tests to aid in the treatment of bladder cancer.

Rivus Pharmaceuticals Inc. today announced publication in The Lancet Gastroenterology & Hepatology of the results of a Phase 2a metabolic study of HU6, an investigational first-in-class controlled metabolic accelerator (CMA), in patients with nonalcoholic fatty liver disease (NAFLD), also known as metabolic dysfunction-associated steatotic liver disease (MASLD), and a high body mass index (BMI).

GC Biopharma Corp. announced that GC1126A, its drug candidate for Thrombotic Thrombocytopenic Purpura, received an Orphan Drug Designation on September 27 from the U.S. Food and Drug Administration.

Verisante Technology, Inc. previously announced on September 7, 2023, that it had agreed to convert certain payables owed to Creditors into common shares in the capital of the Company.

Spartan Medical Inc., a veteran-owned medical solutions company, is launching a campaign to raise awareness about the consequences of Surgical Site Infections and reduce SSIs in medical centers across the country.

Kineta, Inc. announced that it has closed its previously announced registered direct offering for the purchase and sale of 890,208 shares of the Company’s common stock at a purchase price of $3.37 per share of common stock priced at-the-market under Nasdaq rules.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.

Athira Pharma, Inc. (NASDAQ: ATHA) presented new preclinical data supporting the potential benefit of ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS) at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting, taking place October 4-6, 2023, virtually and in-person in Clearwater, Florida.